Axsome Therapeutics Inc
AXSM
Market Cap$5.31B
Close$
$20.34
81.1% downside
Current Fair Value
81.1% downsideOvervalued by 81.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.31 Billion |
|---|---|
| Enterprise Value | $5.21 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-5.99 |
| Beta | 0.45 |
| Outstanding Shares | 48,871,163 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -18.93 |
|---|---|
| PEG | -489.86 |
| Price to Sales | 17.96 |
| Price to Book Ratio | 107.76 |
| Enterprise Value to Revenue | 15.41 |
| Enterprise Value to EBIT | -16.29 |
| Enterprise Value to Net Income | -17 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 3.94 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Axsome Therapeutics Inc
CEO: Herriot Tabuteau Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people facing unsatisfactory tre...